MRRS adds "Frontier Pharma: Ophthalmology Therapeutics – Advancements in Disease Understanding Pave Way for Increasingly Diverse Therapeutic Options, with Age-Related Macular Degeneration and Glaucoma Leading the Way" latest studies, published in November 2016. It is a professional and in-depth study.

Summary
The visual system, including the eye and its surrounding structures, can be affected by a number of pathological conditions. Ophthalmology encompasses a diverse range of indications affecting this system. Key diseases within this therapy area include glaucoma, age-related macular degeneration, diabetic macular edema, diabetic retinopathy and dry eye syndrome.

While treatments for dry eye syndrome are generally able to control its symptoms in the majority of patients, the other four diseases are progressive, chronic, incurable and can lead to visual impairment and even blindness if not adequately treated. Treatment is aimed at managing the disease, in order to reduce the severity of symptoms and to slow progression, rather than being curative.

Scientific advancements over recent decades have revealed a broad range of novel potential molecular targets, enabling progress in a previously stagnant field. This is reflected by the high number of products in development, with 782 pipeline products currently in the ophthalmology therapy area pipeline.

Moreover, there are a total of 158 first-in-class pipeline products in development for ophthalmology indications, representing 36% of the 438 pipeline products for which there is a disclosed molecular target. They appear generally promising in terms of safety and efficacy, and appear to have significant potential to strengthen the treatment landscape for key ophthalmological conditions – as well as representing promising commercial opportunities.

Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 5
2.1 Market Landscape Poised for Entry of Novel Products 5
2.2 Moderately-Sized but Strong First-in-Class Pipeline 5
2.3 Strong Uptake of First-in-Class Products in Strategic Consolidations 5
3 The Case for Innovation 6
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Product Development Remains Attractive 7
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 8
4 Clinical and Commercial Landscape 9
4.1 Therapy Area Overview 9
4.1.1 Glaucoma 9
4.1.2 Age-related Macular Degeneration 9
4.1.3 Diabetic Macular Edema 9
4.1.4 Diabetic Retinopathy 9
4.1.5 Dry Eye Syndrome 10
4.2 Disease Symptoms 10
4.3 Epidemiology and Etiology 12
4.3.1 Glaucoma 12
4.3.2 Age-related Macular Degeneration 12
4.3.3 Diabetic Retinopathy and Diabetic Macular Edema 12
4.3.4 Dry Eye Syndrome 12
4.4 Diagnosis 13
4.5 Pathophysiology 13
4.5.1 Healthy Eye Physiology 13
4.5.2 Glaucoma 14
4.5.3 Age-related Macular Edema 15
4.5.4 Diabetic Macular Edema and Diabetic Retinopathy 16
4.6 Treatment Options 17
4.7 Prognosis 19......

List of Tables and Figures 
Table 1: Ophthalmology Therapeutics Market, Main Symptoms of Glaucoma, AMD, DR and DES, 2016 11
Table 2: Ophthalmology Therapeutics Market, Prevalence of Major Ophthalmologic Disorders, 2016 12
Table 3: Ophthalmology Therapeutics Market, Treatment options available for glaucoma, 2016 18
Table 4: Ophthalmology Therapeutics Market, Data for RPE65 as a Molecular Target, 2016 40
Table 5: Ophthalmology Therapeutics Market, Data for RBP4 as a Molecular Target, 2016 40
Table 6: Ophthalmology Therapeutics Market, Data for CCR 3 as a Molecular Target, 2016 42
Table 7: Ophthalmology Therapeutics Market, Data for Eotaxin-1 as a Molecular Target, 2016 42
Table 8: Ophthalmology Therapeutics Market, Data for LRP6 as a Molecular Target, 2016 44
Table 9: Ophthalmology Therapeutics Market, Data for TGF- Beta 2 as a Molecular Target, 2016 45
Table 10: Ophthalmology Therapeutics Market, Data for LNGFR as a Molecular Target, 2016 46
Table 11: Ophthalmology Therapeutics Market, Data for TrkA as a Molecular Target, 2016 47
Table 12: Ophthalmology Therapeutics Market, Data for NGF as a Molecular Target, 2016 47
Table 13: Ophthalmology Therapeutics Market, Data for Serine Protease HTRA1 as a Molecular Target, 2016 48.....

Browse Complete Report with TOC @
http://www.marketresearchreportstore.com/shop/frontier-pharma-ophthalmology-therapeutics-advancements-in-disease-understanding-pave-way-for-increasingly-diverse-therapeutic-options-with-age-related-macular-degeneration-and-glaucoma-leading-th

About Market Research Report Store
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.

Ask a sample and any further questions, please feel free to contact us:
Tel: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/